New pill aims to stop chronic hives fast when antihistamines fail
NCT ID NCT07665996
First seen Jun 25, 2026 · Last updated Jul 01, 2026 · Updated 2 times
Summary
This early-phase trial tests a new drug called TLL-018 in 36 adults with moderate-to-severe chronic spontaneous urticaria (hives) that standard antihistamines can't control. The goal is to see how quickly TLL-018 reduces itching and hives after the first dose. Participants will receive either 10 mg, 20 mg, or a placebo twice daily for a short period.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TLL-018
What this could lead to
If it works, this could point toward a faster-acting treatment option for people with chronic hives that don't respond to standard antihistamines.
What could go wrong
This is a very early, small trial (36 people) testing rapid onset only. The drug may not work or could have side effects. Results may not apply to everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC SPONTANEOUS URTICARIA (CSU) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Second People's Hospital of Chengdu
Chengdu, Sichuan, China